Cholera Oral Vaccine from Japan
Inactivated oral vaccine with recombinant B-subunit and killed whole cells for cholera prevention in travelers. HTS 3002.49.0050 applies as an 'other' microbial culture-based vaccine for prophylactic human use. Not yeast-derived, fitting chapter exclusions.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• File FDA prior notice 72 hours pre-arrival; ensure tamper-evident packaging for oral suspension
• Provide WHO prequalification if available; document GMO status for biotech-derived components